The reason I ask is that witnesses at this committee have said that if we were to have a universal pharmacare system in this country that was an extension of the Canada Health Act, then they estimate that there would be an additional cost because you're covering more people, but that it would be offset by savings from these different areas.
I think the committee's interested in having some objective analysis of whether that may be the case, so that's why I'm asking.